Public Employees Retirement System of Ohio Buys Shares of 50,077 IQVIA Holdings Inc. $IQV

Key Points

• Public Employees Retirement System of Ohio purchased 50,077 IQVIA shares worth approximately $9.7 million during the second quarter. Institutional investors and hedge funds collectively own 89.62% of the company.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $241.88; several firms recently raised their targets to as high as $288.
• IQVIA exceeded quarterly expectations with adjusted earnings of $3.15 per share and revenue of $4.37 billion, while approving a $2 billion buyback plan covering up to 6.8% of outstanding shares.

Public Employees Retirement System of Ohio purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 50,077 shares of the medical research company's stock, valued at approximately $9,676,000.

Several other institutional investors have also made changes to their positions in the company. Financial Freedom LLC bought a new position in IQVIA during the first quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA during the 1st quarter worth $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at $27,000. Compass Financial Management LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in IQVIA in the fourth quarter worth $27,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on IQV. Barclays reaffirmed an "overweight" rating on shares of IQVIA in a research report on Tuesday, July 28th. Mizuho increased their price objective on IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a report on Monday, July 13th. William Blair upgraded IQVIA to a "strong-buy" rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. upped their target price on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Finally, TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $241.88.

IQVIA Trading Down 0.2%

Shares of NYSE:IQV opened at $261.29 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock's 50-day moving average is $224.00 and its 200-day moving average is $190.15. The company has a market cap of $43.01 billion, a P/E ratio of 32.42, a P/E/G ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $265.25.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm's revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company's stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider W Richard Staub sold 5,500 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,913 shares of company stock valued at $3,098,793 in the last three months. 1.70% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.